After falling sharply last week in the wake of the publication of its annual results, Carmat rebounded on Monday morning on the Paris Bourse after reporting a certain amount of progress in its ongoing clinical study.

The medical technology company claims to have passed the milestone of 20 patients implanted with its artificial heart as part of the study, which already represents 38% of the 52 planned inclusions in total.

Stéphane Piat, the company's CEO, points out that "the interim results of the study are better than expected, at a time when we are treating increasingly sick patients".

The study, called "Eficas" and taking place exclusively in 10 hospitals in France, should be completed as planned in the first half of 2025, with the aim of marketing authorization in the USA by 2027.

In this context, Carmat reiterates its sales forecast of around 14 million euros for 2024, but with a financial horizon currently limited to the end of May 2024.

In a press release, the group - which estimates its 12-month financing requirement at around 45 million euros - says it is working "very actively" on strengthening its equity capital with the participation, already confirmed, of some of its reference shareholders.

Following this market update, Carmat's share price climbed by over 12% in early trading on the Paris Bourse on Monday morning.

The share price had fallen by 20% last week following the announcement of annual sales for 2023 of 2.8 million euros, against a consensus target of four million euros.

For the record, the company had set itself a sales target of ten million euros at the start of the year.

Copyright (c) 2024 CercleFinance.com. All rights reserved.